NGL Fine-Chem Reports Stellar FY26 Performance

Consolidated Revenue: ₹500.95 crore (FY26) vs ₹368.26 crore (FY25)
Consolidated PAT: ₹48.13 crore (FY26) vs ₹21.12 crore (FY25)

Reader Takeaway: Strong revenue and profit growth driven by volume; Tarapur expansion key for future.

What just happened

NGL Fine-Chem announced its financial results for the fiscal year ending March 31, 2026 (FY26). The company posted a consolidated revenue of ₹500.95 crore, a significant increase of 36.03% compared to ₹368.26 crore in FY25. Consolidated Profit After Tax (PAT) saw a substantial jump of 127.82%, reaching ₹48.13 crore from ₹21.12 crore in the previous year.

Why this matters

This robust performance indicates strong demand for NGL Fine-Chem's products and successful operational improvements. The significant profit growth suggests effective cost management and enhanced efficiency, crucial for sustained shareholder returns. The company's continued investment in expansion and focus on regulated markets position it for future growth.

The backstory

NGL Fine-Chem supplies active pharmaceutical ingredients (APIs) primarily for the animal health sector, serving five of the top ten global animal health companies. The company has been focusing on scaling up operations to cater to higher-value, regulated markets, which typically offer better margins and longer-term contracts.

What changes now

The company has invested ₹182.75 crore in its Tarapur greenfield expansion project, which is nearing completion. Phase I is operational, and Phase II is expected to be commissioned in early Q2FY27, with commercial production commencing in H2FY27. This expansion will significantly boost manufacturing capacity. The Board has also recommended a final dividend of ₹1.75 per equity share.

Risks to watch

While performance is strong, investors should monitor potential project cost inflation, as the Tarapur project cost has been revised to ₹210 crore. Additionally, pricing pressures in some veterinary API categories, noted by management, require continued attention to the company's ability to pass on costs.

Peer comparison

NGL Fine-Chem operates in the specialized API segment for animal health, a niche but growing market. Its peers would include other API manufacturers focusing on veterinary or human health segments that also supply to global pharmaceutical majors. The company's specific focus on supplying to the top global animal health companies is a key differentiator.

Context metrics (time-bound)

• Consolidated Revenue (FY26): ₹500.95 crore (up 36.03% from FY25)
• Consolidated PAT (FY26): ₹48.13 crore (up 127.82% from FY25)
• Tarapur Greenfield Expansion Investment (as of March 31, 2026): ₹182.75 crore
• Recommended Final Dividend: ₹1.75 per equity share

What to track next

Investors should closely monitor the commissioning and ramp-up of Phase II of the Tarapur expansion project. Successful execution will be critical for realizing future capacity growth. Additionally, tracking the company's ability to navigate input cost volatility and maintain margin expansion will be key.